Effect of ultra-low-dose estradiol and dydrogesterone on arterial stiffness in postmenopausal women

Climacteric

Volumn 17, Issue 2, 2014, Pages 191-196

  Matsui, S ^a   Yasui, T ^a   Tani, A ^a   Kato, T ^a   Uemura, H ^a   Kuwahara, A ^a   Matsuzaki, T ^a   Arisawa, K ^a   Irahara, M ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Arterial Stiffness; Pulse Wave Velocity; Ultra Low Dose Estradiol

Indexed keywords

CHOLESTEROL; DYDROGESTERONE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ESTRADIOL; FOLLITROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOLUBLE INTERCELLULAR ADHESION MOLECULE 1; SOLUBLE VASCULAR CELL ADHESION MOLECULE 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTERIAL STIFFNESS; ARTICLE; BODY MASS; BRACHIAL ANKLE PULSE WAVE VELOCITY; CALORIMETRY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LOW DRUG DOSE; MIDDLE AGED; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; BLOOD; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG COMBINATION; ESTROGEN THERAPY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; DYDROGESTERONE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84896359736     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2013.856399     Document Type: Article

References (28)

1. Asmar R, Benetos A, Topouchian J, et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 1995; 26: 485-90
2. Thijssen D H, Black M A, Pyke K E, et al. Assessment of flowmediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol 2011; 300: H2-12
3. Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 2004; 24: 571-6 (Pubitemid 38326155)
4. Sumino H, Ichikawa S, Ohyama Y, et al. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women. Am J Cardiol 2005; 96: 148-53 (Pubitemid 40853961)
5. Gambacciani M, Monteleone P, Vitale C, et al. Dydrogesterone does not reverse the effects of estradiol on endotheliumdependant vasodilation in postmenopausal women: a randomised clinical trial. Maturitas 2002; 43: 117-23 (Pubitemid 35217771)
6. Hashimoto M, Miyao M, Akishita M, et al. Effects of long-term and reduced-dose hormone replacement therapy on endothelial function and intima-media thickness in postmenopausal women. Menopause 2002; 9: 58-64 (Pubitemid 34106165)
7. Sumino H, Ichikawa S, Kasama S, et al. Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women. Hypertens Res 2005; 28: 579-84 (Pubitemid 41387288)
8. Sumino H, Ichikawa S, Kasama S, et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis 2006; 189: 436-42 (Pubitemid 44634490)
9. Miura S, Tanaka E, Mori A, et al. Hormone replacement therapy improves arterial stiffness in normotensive postmenopausal women. Maturitas 2003; 45: 293-8 (Pubitemid 36966742)
10. Kawecka-Jaszcz K, Czarnecka D, Olszanecka A, Rajzer M, Jankowski P. The effect of hormone replacement therapy on arterial blood pressure and vascular compliance in postmenopausal women with arterial hypertension. J Hum Hypertens 2002; 16: 509-16 (Pubitemid 34790343)
11. Äuser M H, Panay N, Archer D F, et al. Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2008; 11: 108-23 (Pubitemid 351451114)
12. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. Arandomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 135: 939-53 (Pubitemid 33131615)
13. Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultralow- dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007; 10: 120-31 (Pubitemid 46482176)
14. Stevenson JC, Durand G, Kahler E, Perty ski T. Oral ultra-low dose continuous combined hormone replacement therapy with 0. 5 mg 17 β-oestradiol and 2. 5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. Maturitas 2010; 67: 227-32
15. Gambacciani M, Cappagli B, Ciaponi M, et al. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas 2008; 59: 2-6 (Pubitemid 351179574)
16. Honjo H, Taketani Y. Low-dose estradiol for climacteric symptoms in Japanese women: a randomized, controlled trial. Climacteric 2009; 12: 319-28
17. Mizunuma H, Taketani Y, Ohta H, et al. Dose effects of oral estradiol on bone mineral density in Japanese women with osteoporosis. Climacteric 2010; 13: 72-83
18. Terauchi M, Honjo H, Mizunuma H, Aso T. Effects of oral estradiol and levonorgestrel on cardiovascular risk markers in postmenopausal women. Arch Gynecol Obstet 2012; 285: 1647-56
19. Yamashina A, Tomiyama H, Takeda K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002; 25: 359-64 (Pubitemid 34752554)
20. Mares P, Dauzat M, Abramovici Y. Hormone replacement therapy with estradiol valerate and cyproterone acetate: effects on endothelium-dependent vasodilatation and arterial wall compliance. Maturitas 2002; 42: 45-53 (Pubitemid 34521721)
21. Teede HJ, Liang YL, Kotsopoulos D, et al. Aplacebo-controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: effects on arterial compliance and endothelial function. Clin Endocrinol (Oxf) 2001; 55: 673-82 (Pubitemid 34204451)
22. Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 1992; 166: 740-5
23. Villa P, Sagnella F, Perri C, et al. Low- and standard-estrogen dosage in oral therapy: dose-dependent effects on insulin and lipid metabolism in healthy postmenopausal women. Climacteric 2008; 11: 498-508
24. Godsland I F, Manassiev N A, Felton C V, et al. Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women. Clin Endocrinol (Oxf) 2004; 60: 541-9 (Pubitemid 38669844)
25. Störk S, von Schacky C, Angerer P. The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. Atherosclerosis 2002; 165: 301-7 (Pubitemid 35333356)
26. Simoncini T, Mannella P, Fornari L, et al. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 2004; 145: 5745-56 (Pubitemid 39564616)
27. Fu XD, Garibaldi S, Gopal S, et al. Dydrogesterone exerts endothelial anti-inflammatory actions decreasing expression of leukocyte adhesion molecules. Mol Hum Reprod 2012; 18: 44-51
28. Seeger H, Mueck AO. Effects of dydrogesterone on the vascular system Gynecol Endocrinol 2007; 23(Suppl 1): 2-8 (Pubitemid 47613710)